Post hoc analyses from the B-type natriuretic peptide for Acute Shortness of Breath Evaluation (BASEL)-II-ICU study suggest an association between beta-blocker usage at admission and improved mortality in patients treated in the intensive care unit for acute respiratory failure. Although this evidence is encouraging, there is a need for a phase 2 proof-of-concept randomized controlled trial of beta-blocker therapy in patients admitted with acute respiratory failure. © 2010 BioMed Central Ltd.
CITATION STYLE
Sweeney, R. M., Devereaux, P. J., & McAuley, D. F. (2010). Beta 2 antagonism in acute respiratory failure. Critical Care. https://doi.org/10.1186/cc9359
Mendeley helps you to discover research relevant for your work.